Chardan Capital Cuts Femasys (NASDAQ:FEMY) Price Target to $8.00

Femasys (NASDAQ:FEMY) had its target price trimmed by Chardan Capital from $10.00 to $8.00 in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Femasys in a research report on Tuesday.

Femasys Trading Down 2.8 %

FEMY opened at $0.95 on Wednesday. The firm has a market cap of $21.82 million, a price-to-earnings ratio of -1.18 and a beta of -2.83. Femasys has a 52 week low of $0.73 and a 52 week high of $2.40. The business’s 50 day moving average is $1.16 and its two-hundred day moving average is $1.15. The company has a quick ratio of 5.93, a current ratio of 3.94 and a debt-to-equity ratio of 0.86.

Femasys (NASDAQ:FEMY) last announced its earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The business had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. On average, research analysts predict that Femasys will post -0.79 EPS for the current year.

Hedge Funds Weigh In On Femasys

Institutional investors and hedge funds have recently made changes to their positions in the stock. CM Management LLC increased its holdings in Femasys by 6.3% in the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock valued at $484,000 after buying an additional 25,000 shares in the last quarter. Aljian Capital Management LLC purchased a new position in Femasys in the 3rd quarter valued at approximately $27,000. XTX Topco Ltd increased its stake in Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Femasys by 9.2% during the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after purchasing an additional 17,473 shares during the last quarter. 65.27% of the stock is owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.